# A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer

> **NCT01326871** · PHASE1,PHASE2 · COMPLETED · sponsor: **Altor BioScience** · enrollment: 68 (actual)

## Conditions studied

- Transitional Cell Carcinoma of Bladder
- Urethra Cancer
- Ureter Cancer
- Malignant Tumor of Renal Pelvis

## Interventions

- **DRUG:** Cisplatin
- **DRUG:** Gemcitabine
- **BIOLOGICAL:** ALT-801

## Key facts

- **NCT ID:** NCT01326871
- **Lead sponsor:** Altor BioScience
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-09-06
- **Primary completion:** 2016-04-11
- **Final completion:** 2016-04-11
- **Target enrollment:** 68 (ACTUAL)
- **Last updated:** 2024-06-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01326871

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01326871, "A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer". Retrieved via AI Analytics 2026-06-07 from https://api.ai-analytics.org/clinical/NCT01326871. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*